Clinical Trials Logo

Sarcopenia clinical trials

View clinical trials related to Sarcopenia.

Filter by:

NCT ID: NCT06468735 Completed - Sarcopenia Clinical Trials

The Relationship Among Sarcopenia, Preperitoneal Fat Thickness and Cholecystectomy

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

The aim of this study was to examine the relationship between sarcopenia and visceral adiposity in participants with and without cholecystectomy. In this way, the long-term effects of cholecystectomy operations, which are commonly performed in the society and thought to be harmless, will be evaluated.

NCT ID: NCT06448871 Recruiting - Metabolic Syndrome Clinical Trials

Ultrasound to Assess Sarcopenia in Prader Willi Syndrome

PWS
Start date: October 17, 2022
Phase:
Study type: Observational

The aim of the study is to examine the clinical applicability of ultrasound as a diagnostic tool for sarcopenia in individuals with PWS by investigating the association between ultrasound-derived measurements, DXA-derived measurements, and sarcopenia-related outcomes.

NCT ID: NCT06438900 Not yet recruiting - Obesity Clinical Trials

Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity

Westernage
Start date: June 15, 2024
Phase:
Study type: Observational

The study aims to explore whether a high level of AGEs (Advanced Glycation end products) derived from the diet may mediate diet-related muscle loss in Western-type diet, influencing the onset and progression of sarcopenia, predisposing to earlier and more severe metabolic consequences, including type 2 diabetes (T2D). The primary objective of the study is to investigate how the accumulation of AGEs is correlated with muscle loss in adult patients with obesity and type 2 diabetes or lipodystrophy in order to identify possible targets to mitigate the metabolic alterations caused by the Western diet (WD). Specifically, circulating AGEs levels on the skin will be evaluated and correlated with the stage of sarcopenia in a group of patients with obesity and a T2D diagnosis. Furthermore, the relationship between disease duration and AGE levels will be assessed. A secondary objective will be to analyze the clinical data obtained to identify metabolites and metabolic pathways responsible for the phenotype induced by the WD. The ultimate aim of the study is therefore to verify whether high levels of AGEs are correlated with an early and/or more pronounced onset of sarcopenia, concurrently with an increase in inflammation and oxidative stress.

NCT ID: NCT06437392 Recruiting - Psoriatic Arthritis Clinical Trials

Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic Arthritis

Start date: June 20, 2023
Phase:
Study type: Observational

The purpose of the study is identify the prevalence of sarcopenia and its associated factors in patients with psoriatic arthritis. Furthermore, we aimed to investigate the predictive contribution of USG in diagnosing sarcopenia by assessing the thickness of the rectus femoris, vastus intermedius, and quadriceps muscles in patients with psoriatic arthritis.

NCT ID: NCT06413030 Enrolling by invitation - Obesity Clinical Trials

Slow Gait Speed as an Indicator of Overweight, Dynapenic Obesity and Sarcopenic Obesity in Elderly People in the Community

SGSF
Start date: February 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate the relationship of gait speed with dynapenic or sarcopenic obesity in community-dwelling older people. The main questions it aims to answer are: - Is slow walking speed related to overweight in older people in the community? - Is slow walking speed related to dynapenic obesity in older people in the community? - Is gait speed related to sarcopenic obesity in older people in the community? Participants will answer a clinical interview to obtain sociodemographic data and will perform the following clinical tests: (1) 10-meter walk test, (2) Anthropometric measurement; (3) Handgrip dynamometry test, (4) Standing dynamometry test and (5) Physical functionality questionnaires.

NCT ID: NCT06407583 Completed - Diabetes Clinical Trials

ProMIO2.0; A Powerful Lifestyle Intervention for Older Adults From Ethnic Minorities

ProMIO2
Start date: May 24, 2022
Phase: N/A
Study type: Interventional

Older adults from ethnic minorities show on average a worse disease risk profile compared to the majority populations. An important risk factor to develop chronic diseases is the loss of muscle mass and functioning, also known as sarcopenia. Several randomized controlled trials (RCTs) showed that the combination of adequate protein intake and physical exercise is most effective to prevent the loss of muscle mass, strength and functioning in older adults. However, until shortly, no intervention that included protein and exercise was available that accounted for the special socio-cultural needs of ethnic minority populations. Therefore the Amsterdam University of Applied Sciences (AUAS) and ProMIO project group developed a cultural sensitive lifestyle intervention with protein and exercise carried out by dieticians and physical therapists to provide a tailored treatment for older adults from ethnic minorities. This project aims to evaluate the effectiveness of this new intervention on protein intake, physical activity behavior, muscle mass, muscle strength, function and quality of life. The cost-effectiveness of this new intervention will also be evaluated.

NCT ID: NCT06403137 Recruiting - Sarcopenia Clinical Trials

Plant Protein Blend and Milk Protein Supplements in Older Individuals

Blend-D2O
Start date: June 20, 2024
Phase: N/A
Study type: Interventional

Background Protein intake is important for skeletal muscle mass maintenance with aging and the ingestion of specifically-timed protein supplements could increase overall protein intake and thereby contribute to skeletal muscle mass maintenance. Recently, more attention has been given to the ingestion of plant-based protein blends as a more sustainable high-quality alternative to milk protein, as a means to increase muscle protein build-up and, as such, support muscle maintenance, especially when consuming suboptimal amounts of protein in the regular diet. Objective To assess the benefit of daily protein supplementation with either a plant-based protein blend or a milk protein on top of a standard diet to stimulate integrated muscle protein synthesis rates in healthy older individuals with and without exercise. Hypotheses It is hypothesized that both the plant protein blend and the milk protein supplement will result in greater muscle protein build-up when compared with a standard diet control condition. It is also hypothesized that exercise will result in greater muscle protein build-up when compared to the resting leg in all conditions, with similar effects of the protein supplements vs the control diet as in the non-exercised leg. This study will show the potential benefit of protein supplementation with alternative protein sources to support skeletal muscle maintenance in older individuals.

NCT ID: NCT06394648 Recruiting - Clinical trials for Geriatric Individuals

Investigation of Sarcopenia and Physical Fitness Levels of Geriatric Individuals Living in Nursing Homes and at Home

Start date: April 5, 2024
Phase:
Study type: Observational

To examine the sarcopenia and physical fitness levels of geriatric individuals living in nursing homes and at home. Considering these aims, our working hypotheses are; H1: There is a difference in sarcopenia level between geriatric individuals living in a nursing home and at home. H2: There is a difference in dynapenia levels between geriatric individuals living in a nursing home and at home. H3: There is a difference in physical fitness between geriatric individuals living in a nursing home and at home.

NCT ID: NCT06393244 Recruiting - Sarcopenia Clinical Trials

A Theory-based Home-based Multi-component Exercise Training Among Older Adults With Type 2 Diabetes Mellitus

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn if a theory-based home-based multi-component exercise training works to prevent sarcopenia in older adults with type 2 diabetes mellitus. It will also learn about the safety of the theory-based home-based multi-component exercise training. The main questions it aims to answer are: - Whether a 12-week theory-based home-based MCE program is effective in decreasing the risk of developing sarcopenia, as well as improving physical activity, glycaemic control, muscle mass, muscle strength, physical performance, cognitive function, depressive mood, and quality of life among the Chinese community-dwelling older patients with T2DM. - What are the underlying mechanisms of the exercise intervention. Researchers will compare the MCE program to a waiting list control group to see if the MCE program works to prevent sarcopenia. Participants will: · Take a MCE program or a waiting list for 6 months

NCT ID: NCT06380777 Recruiting - Sarcopenia Clinical Trials

Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia. Research aims: Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey. Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions. Participants will: Engage in screening and assessment based on inclusion and exclusion criteria. Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals. Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.